it is not a stupidity.
$4 years ago, market was pricing Axiron as a big potential for further revenue increase.
At $0.72, market today is worried next quarter sales will be further reduced.
I think some explanation or interpretation of Q2 figure from ACR (or Lilly) will help to clarify, unfortunately ACR got its mouth firmly shut, that's the worry!
Abbvie had a improved quarter for Androgel, means the market revenue/volume was not deeply impacted. ACr need to tell us why the Q2 is bad for Axiron.
- Forums
- ASX - By Stock
- Not good figures
ACR
acrux limited
Add to My Watchlist
0.00%
!
1.9¢

it is not a stupidity. $4 years ago, market was pricing Axiron...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.747M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.9¢ | $5.562K | 292.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 381825 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 60000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 331825 | 0.019 |
3 | 381800 | 0.018 |
1 | 175000 | 0.017 |
1 | 66732 | 0.015 |
1 | 70000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 60000 | 2 |
0.021 | 177000 | 1 |
0.022 | 18000 | 1 |
0.023 | 73278 | 3 |
0.024 | 254102 | 7 |
Last trade - 15.04pm 20/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |